These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 35883629)

  • 1. Recent Advances in Improving Gene-Editing Specificity through CRISPR-Cas9 Nuclease Engineering.
    Huang X; Yang D; Zhang J; Xu J; Chen YE
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases.
    Kim D; Luk K; Wolfe SA; Kim JS
    Annu Rev Biochem; 2019 Jun; 88():191-220. PubMed ID: 30883196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational rescue of the activity of high-fidelity Cas9 enzymes.
    Vos PD; Gandadireja AP; Rossetti G; Siira SJ; Mantegna JL; Filipovska A; Rackham O
    Cell Rep Methods; 2024 Apr; 4(4):100756. PubMed ID: 38608689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CRISPR/CAS9, the King of Genome Editing Tools].
    Bannikov AV; Lavrov AV
    Mol Biol (Mosk); 2017; 51(4):582-594. PubMed ID: 28900076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli-Responsive Vehicles.
    Cai W; Luo T; Mao L; Wang M
    Angew Chem Int Ed Engl; 2021 Apr; 60(16):8596-8606. PubMed ID: 32385892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating CRISPR/Cas9 genome-editing activity by small molecules.
    Chen S; Chen D; Liu B; Haisma HJ
    Drug Discov Today; 2022 Apr; 27(4):951-966. PubMed ID: 34823004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9.
    Koo T; Lee J; Kim JS
    Mol Cells; 2015 Jun; 38(6):475-81. PubMed ID: 25985872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 in Genome Editing and Beyond.
    Wang H; La Russa M; Qi LS
    Annu Rev Biochem; 2016 Jun; 85():227-64. PubMed ID: 27145843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving CRISPR-Cas9 Genome Editing Efficiency by Fusion with Chromatin-Modulating Peptides.
    Ding X; Seebeck T; Feng Y; Jiang Y; Davis GD; Chen F
    CRISPR J; 2019 Feb; 2():51-63. PubMed ID: 31021236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in therapeutic CRISPR/Cas9 genome editing.
    Savić N; Schwank G
    Transl Res; 2016 Feb; 168():15-21. PubMed ID: 26470680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells.
    Donohoue PD; Pacesa M; Lau E; Vidal B; Irby MJ; Nyer DB; Rotstein T; Banh L; Toh MS; Gibson J; Kohrs B; Baek K; Owen ALG; Slorach EM; van Overbeek M; Fuller CK; May AP; Jinek M; Cameron P
    Mol Cell; 2021 Sep; 81(17):3637-3649.e5. PubMed ID: 34478654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient genome editing in wheat using Cas9 and Cpf1 (AsCpf1 and LbCpf1) nucleases.
    Kim D; Hager M; Brant E; Budak H
    Funct Integr Genomics; 2021 Jul; 21(3-4):355-366. PubMed ID: 33710467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Manipulation Using Fusion Guide RNAs for Cas9 and Cas12a.
    Shin HR; Kweon J; Kim Y
    Methods Mol Biol; 2021; 2162():185-193. PubMed ID: 32926383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of Alternative Nucleases in the Age of CRISPR/Cas9.
    Guha TK; Edgell DR
    Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Updates of the CRISPR/Cas9 Genome Editing System: Novel Approaches to Regulate Its Spatiotemporal Control by Genetic and Physicochemical Strategies.
    Allemailem KS; Almatroudi A; Rahmani AH; Alrumaihi F; Alradhi AE; Alsubaiyel AM; Algahtani M; Almousa RM; Mahzari A; Sindi AAA; Dobie G; Khan AA
    Int J Nanomedicine; 2024; 19():5335-5363. PubMed ID: 38859956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Points of View on the Tools for Genome/Gene Editing.
    Chuang CK; Lin WM
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the CRISPR/Cas system for genome editing in microalgae.
    Zhang YT; Jiang JY; Shi TQ; Sun XM; Zhao QY; Huang H; Ren LJ
    Appl Microbiol Biotechnol; 2019 Apr; 103(8):3239-3248. PubMed ID: 30877356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision genome editing in the CRISPR era.
    Salsman J; Dellaire G
    Biochem Cell Biol; 2017 Apr; 95(2):187-201. PubMed ID: 28177771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.